Business Context and Reporting Period
Company: Skye Bioscience, Inc. (SKYE)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Skye is a clinical-stage biotechnology company focused on developing next-generation molecules targeting G-protein-coupled receptors (GPCRs) to treat obesity and metabolic disorders. Its lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting the cannabinoid receptor 1 (CB1). The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric | 2025 (Year Ended Dec 31) | 2024 (Year Ended Dec 31) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(55,924,814) | $(26,567,123) |
| Operating Loss | $(58,163,565) | $(30,192,718) |
| Research & Development Expenses | $42,361,879 | $18,701,694 |
| General & Administrative Expenses | $15,801,686 | $17,725,741 |
| Cash Used in Operating Activities | $(43,062,529) | $(25,237,480) |
| Cash, Cash Equivalents & Short-Term Investments | $25,737,221 | $68,415,741 |
| Accumulated Deficit | $(186,874,486) | $(130,949,672) |
| Working Capital | $18,888,688 | $66,488,360 |
Note: The filing does not provide specific debt figures as the company's convertible note was fully converted to equity in August 2024. There are no long-term debt obligations listed on the balance sheet as of December 31, 2025.
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by 127% ($23.7 million) year-over-year. This was primarily driven by a $20.7 million increase in contract manufacturing costs to resupply the Phase 2a study and prepare for the Phase 2b study, as well as increased discovery research costs.
- Decreased G&A: General and administrative expenses decreased by 11% ($1.9 million), largely due to lower stock-based compensation and reduced professional fees, partially offset by increased investor relations and marketing costs.
- Cash Position: Cash and cash equivalents decreased significantly from $68.4 million in 2024 to $5.9 million in 2025 (with $19.9 million held in short-term investments), reflecting the heavy burn rate associated with clinical trials.
- Legal Contingency: The estimated legal contingency for the "Cunning Lawsuit" was adjusted in 2024 following a favorable appellate ruling. As of December 31, 2025, the accrued liability stands at $2.1 million.
Guidance, Outlook, and Risks
Clinical Development & Strategy
- Phase 2a Results (CBeyond): In October 2025, the company reported that nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo at the tested dose (200 mg). However, the combination of nimacimab and semaglutide demonstrated clinically meaningful weight loss (-13.2% vs -10.25% for semaglutide alone) with no increase in neuropsychiatric adverse events.
- Strategic Pivot: Management has shifted focus to developing nimacimab primarily as a combination therapy with GLP-1 receptor agonists, while continuing to evaluate monotherapy at higher doses.
- Future Trials: In March 2026, the company initiated an expansion study (Part C) to assess the safety and pharmacokinetics of intravenous (IV) nimacimab. A Phase 2b study is planned but excluded from current cash runway estimates.
Liquidity and Going Concern
- Substantial Doubt: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
- Cash Runway: Management estimates sufficient capital to continue operations through the fourth quarter of 2026, excluding costs for the proposed Phase 2b study and related manufacturing.
- Financing Needs: The company will require substantial additional financing to fund future clinical trials and operations. Access to capital markets is described as "extremely limited."
Key Risks
- Legal Proceedings: The company is subject to the "Cunning Lawsuit" (remanded for a new trial in March 2026) and a putative securities class action lawsuit filed in late 2025 regarding statements about nimacimab.
- Stock Listing: The company's stock price has traded below $1.00 for 39 consecutive trading days, risking delisting from the Nasdaq Global Market if compliance is not regained.
- Personnel: The company experienced the departure of key personnel in Q1 2026, including the Chief Financial Officer, and is relying on contractors to maintain operations.
Investor Verification Checklist
- Cash Runway Validation: Verify the specific timeline for the next capital raise given the Q4 2026 runway estimate and the exclusion of Phase 2b costs.
- Legal Exposure: Monitor the status of the "Cunning Lawsuit" retrial scheduled for March 2026 and the securities class action lawsuit filed in November 2025.
- Nasdaq Compliance: Confirm whether the company has received a delisting notice from Nasdaq and the status of any plan to regain compliance with the $1.00 minimum bid price requirement.
- Phase 2b Funding: Assess the feasibility of securing funding specifically for the Phase 2b study, which is critical for the combination therapy strategy but currently unfunded.
- Management Stability: Review the impact of recent executive departures (CFO) on operational continuity and financial reporting.